faf777 Isomorphic Labs, Google’s A.I. Drug Business, Raises $600 Million

data de lançamento:2025-04-09 03:45    tempo visitado:108

Over the last 12 monthsfaf777, Google’s efforts to use artificial intelligence to accelerate drug design have achieved breakthroughs in mimicking human biology and won its top scientists the Nobel Prize in Chemistry.

Now Isomorphic Labs, the division within the software giant meant to develop and commercialize the technology, is taking another big step: raising money from an outside investor.

Isomorphic announced on Monday that it had raised $600 million, led by Thrive Capital, the venture capital firm that has bet big on A.I. companies including OpenAI. GV, Google’s venture capital arm, and Alphabet, Google’s parent company, also invested.

The announcement underscores Google’s ambitions for Isomorphic, which was spun out of the company’s DeepMind lab to focus on drugs discovery. It is built on software that DeepMind, a central intelligence lab in London, has developed. That includes AlphaFold,66jogo which can predict the structure of millions of proteins and more.

AlphaFold, which in its third iteration can now predict the complex behavior of DNA and RNA, has promised to slash the development time of new drugs. Such is its promise that Demis Hassabis, a co-founder of Isomorphic and DeepMind, and John M. Jumper, a DeepMind researcher, shared half of the Nobel in chemistry last year.

So I was ready to put my mental fighting gloves on as I approached a building superintendent who was blasting the sidewalk ahead of me with a hose.

The new police commissioner would be joining an administration that has been rocked by at least four federal criminal investigations, including one that forced the resignation of Mr. Caban. And the new leader’s time could be short: Mr. Adams is facing what could be a difficult re-election campaign next year.

The goal, according to Mr. Hassabis, is to eventually conduct most of the drug discovery process via computers, rather than traditional labs that require biological materials, strict safety requirements — and lots of time.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.

Thank you for your patience while we verify access.

Already a subscriber? Log in.

pubgpg

Want all of The Times? Subscribe.faf777